EyePoint Pharmaceuticals, Inc. (EYPT) Stock Overview
Explore EyePoint Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
EyePoint Pharmaceuticals, Inc. (EYPT)
Key Financials
Key Financials
Market Cap
446M
P/E Ratio
-1.39
EPS (TTM)
$-3.74
ROE
-1.36%
EYPT Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, EyePoint Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of EYPT on the NASDAQ shows an RSI of 29.64, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $15.28 for the NASDAQ listing.
Key metrics behind EyePoint Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -1.39 and a market capitalization of 446M. Combined with our AI analysis, these give both institutional and retail investors a clear view of EYPT on the NASDAQ.